The genomic profiling of high-risk smoldering myeloma patients treated with an intensive strategy unveils potential markers of resistance and progression

The genomic profiling of high-risk smoldering myeloma patients treated with an intensive strategy unveils potential markers of resistance and progression

Abstract Smoldering multiple myeloma (SMM) precedes multiple myeloma (MM). The risk of progression of SMM patients is not uniform, thus different progression-risk models have been developed, although they are mainly based on clinical parameters. Recently, genomic predictors of progression have been...

Full description

Bibliographic Details
Main Authors: A. Medina-Herrera, I. Vazquez, I. Cuenca, J. M. Rosa-Rosa, B. Ariceta, C. Jimenez, M. Fernandez-Mercado, M. J. Larrayoz, N. C. Gutierrez, M. Fernandez-Guijarro, V. Gonzalez-Calle, P. Rodriguez-Otero, A. Oriol, L. Rosiñol, A. Alegre, F. Escalante, J. De La Rubia, A. I. Teruel, F. De Arriba, M. T. Hernandez, J. Lopez-Jimenez, E. M. Ocio, N. Puig, B. Paiva, J. J. Lahuerta, J. Bladé, J. F. San Miguel, M. V. Mateos, J. Martinez-Lopez, M. J. Calasanz, R. Garcia-Sanz, GEM/PETHEMA (Grupo Español de Mieloma/Programa para el Estudio de la Terapéutica en Hemopatías Malignas) cooperative study group
Format: Article
Language:English
Published: Nature Publishing Group 2024-04-01
Series:Blood Cancer Journal
Online Access:https://doi.org/10.1038/s41408-024-01053-3

Internet

https://doi.org/10.1038/s41408-024-01053-3

Similar Items